Table 2.
Correlations between Clinicopathological Features and DNA Damage Response Proteins in Early-Onset or Familial Gastric Cancer
| BRCA1 | BRCA2 | MRE11 | Rad51C | γH2AX | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Negative | Positive | p | Negative | Positive | p | Negative | Positive | p | Negative | Positive | p | Negative | Positive | p | ||
| Gender | Male | 22 (47.8) | 33 (55) | 0.464 | 14 (38.9) | 38 (58.5) | 0.059 | 12 (66.7) | 43 (49.4) | 0.182 | 8 (50) | 47 (52.2) | 0.87 | 17 (60.7) | 39 (49.4) | 0.302 |
| Female | 24 (52.2) | 27 (45) | 22 (61.1) | 27 (41.5) | 6 (33.3) | 44 (50.6) | 8 (50) | 43 (47.8) | 11 (39.3) | 40 (50.6) | ||||||
| Differentiation | Well differentiated | 0 (0) | 2 (4.2) | 0.462 | 1 (3.3) | 1 (2.1) | 0.195 | 1 (8.3) | 1 (1.4) | 0.336 | 0 (0) | 2 (2.9) | 0.272 | 0 (0) | 2 (3.2) | 0.672 |
| Moderately differentiated | 4 (11.4) | 6 (12.5) | 1 (3.3) | 8 (16.7) | 1 (8.3) | 9 (12.9) | 0 (0) | 10 (14.3) | 3 (14.3) | 7 (11.3) | ||||||
| Poorly differentiated | 31 (88.6) | 40 (83.3) | 28 (93.3) | 39 (81.3) | 10 (83.3) | 60 (85.7) | 13 (100) | 58 (82.9) | 18 (85.7) | 53 (85.5) | ||||||
| Lauren classification | Intestinal | 4 (11.4) | 8 (16.7) | 0.34 | 2 (6.7) | 9 (18.8) | 0.255 | 2 (16.7) | 10 (14.3) | 0.691 | 0 (0) | 12 (17.1) | 0.159 | 3 (14.3) | 9 (14.5) | 1 |
| Diffuse | 28 (80) | 39 (81.3) | 27 (90) | 36 (75) | 10 (83.3) | 56 (80) | 13 (100) | 54 (77.1) | 17 (81) | 50 (80.6) | ||||||
| Mixed | 3 (8.6) | 1 (2.1) | 1 (3.3) | 3 (6.3) | 0 (0) | 4 (5.7) | 0 (0) | 4 (5.7) | 1 (4.8) | 3 (4.8) | ||||||
| T stage | T1 | 8 (22.2) | 13 (26.5) | 0.891 | 8 (26.7) | 11 (22) | 0.833 | 1 (7.7) | 20 (28.2) | 0.115 | 6 (46.2) | 15 (20.8) | 0.083 | 2 (9.1) | 19 (30.2) | 0.154 |
| T2 | 2 (5.6) | 4 (8.2) | 1 (3.3) | 4 (8) | 0 (0) | 6 (8.5) | 2 (15.4) | 4 (5.6) | 2 (9.1) | 4 (6.3) | ||||||
| T3 | 15 (41.7) | 17 (34.7) | 12 (40) | 19 (38) | 5 (38.5) | 27 (38) | 2 (15.4) | 30 (41.7) | 8 (36.4) | 24 (38.1) | ||||||
| T4 | 11 (30.6) | 15 (30.6) | 9 (30) | 16 (32) | 7 (53.8) | 18 (25.4) | 3 (23.1) | 23 (31.9) | 10 (45.5) | 16 (25.4) | ||||||
| LN metastasis | Absent | 13 (35.1) | 15 (30.6) | 0.658 | 13 (41.9) | 13 (26) | 0.135 | 4 (30.8) | 24 (33.3) | 0.856 | 8 (57.1) | 20 (27.8) | 0.032 | 7 (31.8) | 21 (32.8) | 0.932 |
| Present | 24 (64.9) | 34 (69.4) | 18 (58.1) | 37 (74) | 9 (69.2) | 48 (66.7) | 6 (42.9) | 52 (72.2) | 15 (68.2) | 43 (67.2) | ||||||
| TNM stage | I | 8 (19.5) | 15 (27.8) | 0.561 | 8 (23.5) | 12 (21.4) | 0.945 | 1 (5.6) | 22 (28.9) | 0.015 | 7 (50) | 16 (19.8) | 0.044 | 2 (7.7) | 21 (30) | 0.062 |
| II | 19 (46.3) | 20 (37) | 14 (41.2) | 25 (44.6) | 6 (33.3) | 33 (43.4) | 3 (21.4) | 36 (44.4) | 14 (53.8) | 25 (35.7) | ||||||
| III | 14 (34.1) | 19 (35.2) | 12 (35.3) | 19 (33.9) | 11 (61.1) | 21 (27.6) | 4 (28.6) | 29 (35.8) | 10 (38.5) | 24 (34.3) | ||||||